Drug intelligence / Profile preview

D150

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D150 is a pharmaceutical drug code primarily investigated for its role in the treatment of Type 2 Diabetes Mellitus. It is frequently studied in combination with other investigational compounds such as CKD-501, D759, D745, CKD-379, CKD-378, and CKD-383. Clinical trials involving D150 have focused on evaluating pharmacokinetic drug interactions, safety, and efficacy as part of combination therapies for patients whose blood glucose levels are not adequately controlled by existing treatments.

Beyond the preview

Go deeper on D150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D150.

Explore the full profile